Cabozantinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3Prostate Cancer · Phase 3

Also approved (6)
US
  • Cabozantinib to treat: • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors. • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors
    FDA label
  • COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).FDA label
  • Differentiated Thyroid Cancer CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
    FDA label
  • Neuroendocrine Tumors CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
    FDA label
Product first approved 2012Outside this platform's coverage
CA
  • Renal Cell Carcinoma (RCC) CABOMETYX (cabozantinib) is indicated for the treatment of advanced RCC: • In treatment-naïve adults with intermediate or poor risk. • In adult patients who have received prior therapy. CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC. Hepatocellular Carcinoma (HCC) CABOMETYX is indicated for the treatment of patients with HCC who have been previously treated with sorafenib. Differentiated Thyroid Carcinoma (DTC) CABOMETYX...
Product first approved 2018Health Canada
EU
  • Cabometyx (Ipsen Pharma): advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid carcinoma and neuroendocrine tumours (EU marketing authorisation EMEA/H/C/004163)
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (20)
Clear Cell Renal Cell Carcinoma
NCT03793166 · National Cancer Institute (NCI)
2019-06-07 – 2028-03-01 · Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Prostate Cancer
NCT01522443 · Exelixis
2012-03 – 2015-01-13 · Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
What this study did
Renal Cell Carcinoma
NCT03937219 · Exelixis
2019-06-25 – 2027-01-31 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07871864 · Gustave Roussy, Cancer Campus, Grand Paris
2026-10-07 – 2036-01 · Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, Osteosarcoma Metastatic
What this study did
NCT07405164 · Merck Sharp & Dohme LLC
2026-03-23 – 2034-04-22 · Von Hippel-Lindau Disease, Malignant Neoplasms
What this study did
NCT06364631 · Gustave Roussy, Cancer Campus, Grand Paris
2024-04-12 – 2032-05-05 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
What this study did
NCT06475989 · ECOG-ACRIN Cancer Research Group
2024-12-27 – 2030-09-30 · Refractory Differentiated Thyroid Gland Carcinoma
What this study did
NCT05092958 · National Cancer Institute (NCI)
2022-06-03 – 2029-07-15 · Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
What this study did
NCT03768063 · Hoffmann-La Roche
2019-02-28 – 2028-07-05 · Cancer
What this study did
NCT03375320 · National Cancer Institute (NCI)
2018-10-26 – 2027-09-01 · Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
What this study did
NCT00704730 · Exelixis
2008-06 – 2020-09 · Thyroid Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05691478 · National Cancer Institute (NCI)
2023-03-03 – 2030-03-20 · High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
What this study did
Phase 2 (145)
Clear Cell Renal Cell Carcinoma
NCT05361720 · Vanderbilt-Ingram Cancer Center
2022-12-06 – 2028-07-01 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03634540 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2018-09-27 – 2027-02-26 · Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
What this study did
NCT04022343 · Emory University
2019-08-06 – 2026-12-09 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
What this study did
Hepatocellular Carcinoma
NCT04588051 · Stephen Chan Lam
2020-11-01 – 2028-12-31 · HCC
What this study did
NCT07151326 · National Health Research Institutes, Taiwan
2025-09 – 2028-06 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05327738 · OHSU Knight Cancer Institute
2022-12-10 – 2027-12-04 · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
What this study did
NCT04472767 · University of California, Irvine
2020-08-07 – 2027-09-01 · Hepatocellular Carcinoma, HCC
What this study did
NCT02867592 · National Cancer Institute (NCI)
2017-05-18 – 2027-06-28 · Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
What this study did
NCT05168163 · Academic and Community Cancer Research United
2022-05-27 – 2026-12-31 · Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
NCT06535737 · Chulalongkorn University
2024-08 – 2026-12 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT04204850 · University Health Network, Toronto
2020-08-07 – 2026-06-30 · Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
What this study did
NCT03899428 · Humanity & Health Medical Group Limited
2019-05-02 – 2025-12-31 · Hepatocellular Carcinoma
What this study did
NCT04511455 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-12-08 – 2024-12-31 · Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
What this study did
NCT04522908 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-10-12 – 2024-10-04 · Hepatocellular Carcinoma (HCC), Second Line Treatment
What this study did
NCT04767906 · University of Leipzig
2021-12-14 – 2024-07-19 · Hepatocellular Carcinoma
What this study did
NCT04454762 · Johannes Gutenberg University Mainz
2020-07-22 – 2024-02-01 · Hepatocellular Carcinoma
What this study did
NCT04435977 · Istituto Clinico Humanitas
2020-01-30 – 2023-09 · Hepatocarcinoma
What this study did
NCT04316182 · Fundacion Clinic per a la Recerca Biomédica
2020-07-31 – 2023-02-22 · Hepatocellular Carcinoma
What this study did
NCT04442581 · University of Washington
2021-04-20 – 2022-03-08 · Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
What this study did
NCT03586973 · Takeda
2018-08-06 – 2021-06-29 · Advanced Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT05613413 · University of Illinois at Chicago
2022-12-28 – 2028-09 · Metastatic Squamous Non-Small Cell Lung Carcinoma
What this study did
NCT05859217 · Jun Zhang, MD, PhD
2024-12 – 2028-06 · Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
What this study did
NCT01639508 · Memorial Sloan Kettering Cancer Center
2012-07 – 2027-07 · Non-Small Cell Lung Cancer
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT01708954 · National Cancer Institute (NCI)
2013-02-13 – 2027-03-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT03468985 · National Cancer Institute (NCI)
2018-05-07 – 2022-12-21 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT04131543 · University of Bologna
2019-08-07 – 2022-08-07 · Non Small Cell Lung Cancer
What this study did
NCT03911193 · Fondazione Ricerca Traslazionale
2018-09-21 – 2020-09 · Non-Small Cell Lung Cancer
What this study did
NCT02132598 · Liza Villaruz, MD
2015-12 – 2019-08-09 · Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
What this study did
NCT01866410 · National Cancer Institute (NCI)
2013-05-20 – 2018-03-30 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
Prostate Cancer
NCT05502315 · Rana McKay, MD
2023-02-02 – 2027-11-12 · Castration-resistant Prostate Cancer, Metastatic Cancer
What this study did
NCT05168618 · University of Utah
2022-03-29 – 2027-11 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT04631744 · Weill Medical College of Cornell University
2021-03-03 – 2025-11-09 · Prostate Cancer
What this study did
NCT03964337 · Duke University
2020-03-17 – 2021-06-04 · Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
What this study did
NCT01630590 · M.D. Anderson Cancer Center
2014-01-08 – 2021-04-06 · Prostate Cancer
What this study did
NCT01588821 · Massachusetts General Hospital
2012-06 – 2019-06 · Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
What this study did
NCT01599793 · University of Chicago
2012-05 – 2018-12 · Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT01834651 · Edwin Posadas, MD
2013-04-30 – 2016-07-18 · Prostate Cancer
What this study did
NCT01703065 · University of Washington
2013-06-18 – 2015-09-18 · Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT01428219 · University of Michigan Rogel Cancer Center
2012-02 – 2015-09 · Prostate Cancer Metastatic
What this study did
NCT01995058 · Exelixis
2014-02 – 2014-11 · Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
What this study did
Renal Cell Carcinoma
NCT05931393 · University of Texas Southwestern Medical Center
2023-12-20 – 2029-12-31 · RCC, Renal Cell Carcinoma
What this study did
NCT07077161 · dr. Tom van der Hulle
2026-01-26 – 2028-09-01 · Renal Cell Carcinoma (RCC)
What this study did
NCT04322955 · Mark Stein
2020-06-22 – 2028-02 · Kidney Cancer, Renal Cell Carcinoma
What this study did
NCT05048212 · M.D. Anderson Cancer Center
2022-09-20 – 2027-12-31 · Brain Metastases, Renal Cell Carcinoma
What this study did
NCT03635892 · Memorial Sloan Kettering Cancer Center
2018-08-13 – 2027-08 · Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
What this study did
NCT03541902 · M.D. Anderson Cancer Center
2018-05-15 – 2027-07-31 · Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
What this study did
NCT04413123 · Bradley A. McGregor, MD
2020-11-05 – 2027-06-20 · Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
What this study did
Phase 1/2 (20)
Clear Cell Renal Cell Carcinoma
NCT05663710 · M.D. Anderson Cancer Center
2023-06-30 – 2027-10-30 · Advanced Cancer, Clear Cell Renal Cell Carcinoma
What this study did
NCT06835972 · Memorial Sloan Kettering Cancer Center
2025-02-14 – 2027-02 · Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
What this study did
NCT04300140 · Aravive, Inc.
2021-02-26 – 2023-08-14 · Clear Cell Renal Cell Carcinoma
What this study did
Hepatocellular Carcinoma
NCT03539822 · Anwaar Saeed
2018-10-22 – 2029-06-30 · Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
What this study did
NCT05797805 · Iterion Therapeutics
2023-09-13 – 2026-06 · Advanced Hepatocellular Carcinoma
What this study did
NCT04497038 · University of Michigan Rogel Cancer Center
2021-08-06 – 2023-05-02 · Advanced Adult Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04151563 · Bristol-Myers Squibb
2021-04-15 – 2026-05-13 · Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT00596648 · Exelixis
2008-02-12 – 2012-08-02 · Carcinoma, Non-Small-Cell Lung
What this study did
Prostate Cancer
NCT01683994 · National Cancer Institute (NCI)
2012-09-07 – 2019-01-16 · Prostatic Neoplasms
What this study did
Renal Cell Carcinoma
NCT07293351 · Bristol-Myers Squibb
2026-03-26 – 2031-11-26 · Advanced Renal Cell Carcinoma (RCC)
What this study did
NCT03149822 · University of Colorado, Denver
2017-09-28 – 2024-02-16 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT05048901 · National Health Research Institutes, Taiwan
2021-09-17 – 2027-12-31 · Neuroendocrine Tumors,Gastroenteropancreatic
What this study did
NCT05039281 · M.D. Anderson Cancer Center
2022-09-23 – 2027-12-31 · Recurrent Glioblastoma, Recurrent Gliosarcoma
What this study did
NCT03957551 · John Rieth
2019-08-27 – 2025-10-17 · Advanced Metastatic Melanoma
What this study did
NCT04220229 · University of Washington
2020-06-01 – 2024-10-31 · Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
What this study did
NCT03425201 · Fundacion CRIS de Investigación para Vencer el Cáncer
2019-10-14 – 2024-07-31 · Urothelial Cancer
What this study did
NCT03201250 · University of Nebraska
2018-02-21 – 2021-04-12 · Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
What this study did
NCT01866293 · Memorial Sloan Kettering Cancer Center
2013-05-28 – 2016-08-18 · Relapsed or Refractory Multiple Myeloma
What this study did
Phase 1 (47)
Clear Cell Renal Cell Carcinoma
NCT07848295 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2026-12-31 – 2031-04-17 · Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT07187869 · M.D. Anderson Cancer Center
2026-02-12 – 2029-04-07 · Clear Cell Renal Cell Carcinoma
What this study did
NCT05536141 · Arcus Biosciences, Inc.
2022-10-26 – 2029-03 · Clear Cell Renal Cell Carcinoma, Solid Tumors
What this study did
NCT02496208 · National Cancer Institute (NCI)
2015-07-22 – 2027-07-30 · Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
What this study did
NCT06026410 · Kura Oncology, Inc.
2023-10-18 – 2027-04 · Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
What this study did
NCT05122546 · City of Hope Medical Center
2021-11-01 – 2027-01-12 · Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Clear Cell Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
What this study did
NCT02293980 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2014-11-25 – 2026-11-30 · ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
What this study did
NCT05188118 · Icahn School of Medicine at Mount Sinai
2023-02-15 – 2025-04-30 · Renal Cell Carcinoma
What this study did
Hepatocellular Carcinoma
NCT05092373 · M.D. Anderson Cancer Center
2022-04-29 – 2026-09-01 · Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT03299946 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-05-14 – 2021-10-01 · Locally Advanced Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT03170960 · Exelixis
2017-09-05 – 2027-09-30 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
What this study did
NCT04514484 · National Cancer Institute (NCI)
2021-11-22 – 2027-02-06 · Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
What this study did
NCT04173338 · Augusta University
2020-01-23 – 2022-03-28 · Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
What this study did
NCT01553656 · Exelixis
2011-02 – 2015-07 · Solid Tumors, Cancer, NSCLC
What this study did
Prostate Cancer
NCT05613894 · University of Utah
2023-07-14 – 2028-12 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT04477512 · Washington University School of Medicine
2021-02-19 – 2025-09-10 · Metastatic Hormone Refractory Prostate Cancer
What this study did
NCT01574937 · Dana-Farber Cancer Institute
2012-04-03 – 2021-07-01 · Prostate Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01347788 · Massachusetts General Hospital
2011-04 – 2013-05 · Prostate Adenocarcinoma
What this study did
Renal Cell Carcinoma
NCT06132945 · Memorial Sloan Kettering Cancer Center
2023-11-10 – 2027-11 · Metastatic Renal Cell Carcinoma, Brain Metastases
What this study did
NCT03798626 · Novartis Pharmaceuticals
2019-05-22 – 2025-02-05 · Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
What this study did
NCT03200587 · University of Utah
2018-06-21 – 2021-11-25 · Renal Cell Carcinoma
What this study did
NCT01100619 · Exelixis
2010-04 – 2012-08 · Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06502171 · Girish Dhall, MD
2026-06-09 – 2034-08-01 · Neurofibromatosis 1, Plexiform Neurofibroma
What this study did
NCT07194044 · H. Lee Moffitt Cancer Center and Research Institute
2026-02-05 – 2030-10 · Metastatic Ewing Sarcoma
What this study did
NCT05249114 · Providence Health & Services
2022-12-28 – 2029-12 · Neuroendocrine Tumors
What this study did
NCT04878029 · Emory University
2021-07-23 – 2028-12-21 · Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT06156410 · Children's Hospital of Philadelphia
2023-10-24 – 2028-11 · Ewing Sarcoma, Osteosarcoma, Sarcomas
What this study did
NCT03816345 · National Cancer Institute (NCI)
2019-07-16 – 2028-03-30 · Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
What this study did
NCT05038839 · M.D. Anderson Cancer Center
2022-02-09 – 2026-05-05 · Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
What this study did
NCT03611595 · Peter Zage
2018-08-28 – 2026-03-23 · Solid Tumor
What this study did
NCT03667482 · Memorial Sloan Kettering Cancer Center
2018-09-07 – 2024-07-17 · Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer
What this study did
NCT04868773 · University of California, Irvine
2021-07-16 – 2024-04-09 · Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer, CRC
What this study did
NCT04661852 · Dana-Farber Cancer Institute
2020-12-23 – 2022-10-24 · Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
What this study did
NCT01822522 · National Cancer Institute (NCI)
2013-06-21 – 2021-05-12 · Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Solid Neoplasm
What this study did
NCT01709435 · National Cancer Institute (NCI)
2012-11-14 – 2019-12-31 · Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Thyroid Gland Medullary Carcinoma
What this study did
NCT02008383 · John Strickler, M.D.
2014-01 – 2018-08-29 · Colorectal Cancer
What this study did
NCT01663272 · University of Michigan Rogel Cancer Center
2012-07 – 2017-03-01 · Pancreatic Cancer
What this study did
NCT01961765 · Massachusetts General Hospital
2013-11 – 2017-01 · Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT01582295 · Massachusetts General Hospital
2012-06 – 2014-11 · Multiple Myeloma
What this study did
NCT01835184 · National Cancer Institute (NCI)
2013-05 – 2014-09 · Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01493869 · Exelixis
2011-09 – 2014-08 · Healthy, Hepatic Impairment
What this study did
NCT01761773 · Exelixis
2012-12 – 2014-07 · Healthy, Renal Impairment
What this study did
NCT00960492 · Exelixis
2009-09 – 2013-10 · Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
What this study did
NCT00215605 · Exelixis
2005-09 – 2012-07 · Lymphoma, Cancer, Thyroid Carcinoma
What this study did
NCT01018745 · Bristol-Myers Squibb
2010-01 – 2010-07 · Neoplasms
What this study did
Phase 4 (5)
Hepatocellular Carcinoma
NCT03963206 · Hospices Civils de Lyon
2019-09-09 – 2021-10-07 · Hepatocellular Carcinoma
What this study did
Renal Cell Carcinoma
NCT07028125 · Centre Francois Baclesse
2025-10-01 – 2029-01 · Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
What this study did
NCT06934057 · Gustave Roussy, Cancer Campus, Grand Paris
2025-05-16 – 2028-04 · Kidney Cancer, Renal Cell Cancer
What this study did
Other / comorbidity
NCT01896479 · Exelixis
2015-02-25 – 2035-01-31 · Medullary Thyroid Cancer
What this study did
NCT07010393 · Fujian Medical University
2025-07-01 – 2028-12-31 · Thyroid Neoplasms
What this study did
Early phase / not applicable (4)
Prostate Cancer
NCT01812668 · Barbara Ann Karmanos Cancer Institute
2013-03 – 2019-06-18 · Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
Renal Cell Carcinoma
NCT07805122 · Centro di Riferimento Oncologico - Aviano
2026-05-19 – 2030-05-19 · Renal Cell Carcinoma
What this study did
NCT03867045 · Duke University
2019-08-21 – 2019-12-16 · Metastatic Renal Cell Carcinoma Treated With Cabozantinib
What this study did
Other / comorbidity
NCT02592356 · M.D. Anderson Cancer Center
2015-11-16 – 2024-03-01 · Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
Renal Cell Carcinoma
NCT07227402 · Merck Sharp & Dohme LLC
2025-11-26 – 2033-03-21 · Renal Cell Carcinoma
What this study did
NCT04586231 · Merck Sharp & Dohme LLC
2021-02-25 – 2027-02-11 · Carcinoma, Renal Cell
What this study did
Other / comorbidity
NCT04760288 · Hoffmann-La Roche
2023-11-30 – 2035-04-12 · Medullary Thyroid Cancer
What this study did
NCT04211337 · Loxo Oncology, Inc.
2020-02-11 – 2027-11 · Medullary Thyroid Cancer
What this study did
Phase 2 (2)
Clear Cell Renal Cell Carcinoma
NCT05012371 · M.D. Anderson Cancer Center
2022-02-16 – 2027-10-25 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
Other / comorbidity
NCT05773274 · National Cancer Institute (NCI)
2024-01-12 – 2029-04-30 · Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Clear Cell Renal Cell Carcinoma
NCT07383441 · SWOG Cancer Research Network
2026-06-05 – 2034-01-31 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT07011719 · Arcus Biosciences, Inc.
2025-09-08 – 2030-12 · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
What this study did
Renal Cell Carcinoma
NCT06726421 · Sun Yat-sen University
2024-09-18 – 2033-09-30 · Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
What this study did
Phase 2 (5)
Clear Cell Renal Cell Carcinoma
NCT04071223 · National Cancer Institute (NCI)
2020-07-29 – 2027-09-24 · Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
What this study did
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
NCT05411081 · National Cancer Institute (NCI)
2023-03-24 – 2027-07-01 · Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03428217 · Calithera Biosciences, Inc
2018-04-24 – 2021-07-16 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT05127824 · Jodi Maranchie
2023-07-06 – 2027-12 · Carcinoma, Renal Cell
What this study did
Phase 1/2 (1)
Hepatocellular Carcinoma
NCT06811116 · National Cancer Institute (NCI)
2025-11-17 – 2027-08-31 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did

Competitive landscape

This drug's own stage for Clear Cell Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cabozantinib: this drugApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
CasdatifanPhase 3Small moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
DarlifarnibPhase 1Small moleculeFarnesyltransferasenot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
XmAb819Phase 1Multispecific antibodyENPP3 x CD3not yet gradedNo reviewed efficacy summary in this indication
CTX131DiscontinuedCell therapyCD70not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(62 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cabozantinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 2Prostate CancerActive not recruiting
Est. primary completion 2026-11 · NCT05168618 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT05613894 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic SarcomaRecruiting
Est. primary completion 2026-12 · NCT05182164 · CT.gov ↗
What to watch
Phase 2MeningiomaRecruiting
Est. primary completion 2026-12 · NCT05425004 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05263050 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-20 · NCT04413123 · CT.gov ↗
What to watch
2027 (33)
January 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT06026410 · CT.gov ↗
What to watch
Phase 2Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Recruiting
Est. primary completion 2027-01-01 · NCT05136196 · CT.gov ↗
What to watch
Phase 1Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-12 · NCT05122546 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT04472767 · CT.gov ↗
What to watch
February 2027 (4)
Phase 1/2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-02 · NCT06835972 · CT.gov ↗
What to watch
Phase 2Metastatic Soft-tissue SarcomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04551430 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-26 · NCT03634540 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-02-28 · NCT03866382 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Cancer of KidneyNot yet recruiting
Est. primary completion 2027-03 · NCT05241561 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04310007 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-04-07 · NCT07187869 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-05 · NCT04322955 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07 · NCT01639508 · CT.gov ↗
What to watch
Phase 2Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma …Active not recruiting
Est. primary completion 2027-07-15 · NCT05111574 · CT.gov ↗
What to watch
Phase 1Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT02496208 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-07-31 · NCT03541902 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-08 · NCT03635892 · CT.gov ↗
What to watch
Phase 1/2Neuroendocrine Tumors,GastroenteropancreaticRecruiting
Est. primary completion 2027-08-31 · NCT05048901 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-09-01 · NCT07077161 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-09-01 · NCT05931393 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT05361720 · CT.gov ↗
What to watch
Phase 1/2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-30 · NCT05663710 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1Ewing Sarcoma, Osteosarcoma, SarcomasRecruiting
Est. primary completion 2027-11 · NCT06156410 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-11 · NCT06132945 · CT.gov ↗
What to watch
Phase 1Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma …Recruiting
Est. primary completion 2027-11-13 · NCT04878029 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1Neuroendocrine TumorsActive not recruiting
Est. primary completion 2027-12 · NCT05249114 · CT.gov ↗
What to watch
Phase 2Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma …Recruiting
Est. primary completion 2027-12-16 · NCT06006013 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, Recurrent GliosarcomaActive not recruiting
Est. primary completion 2027-12-31 · NCT05039281 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04588051 · CT.gov ↗
What to watch
Phase 2Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable OsteosarcomaRecruiting
Est. primary completion 2027-12-31 · NCT05019703 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05048212 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
2028 (9)
March 2028 (2)
Phase 3Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-03-01 · NCT03793166 · CT.gov ↗
What to watch
Phase 1Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease …Recruiting
Est. primary completion 2028-03-30 · NCT03816345 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2028-04 · NCT06934057 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma …Active not recruiting
Est. primary completion 2028-05-15 · NCT05836571 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-06 · NCT07151326 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT03539822 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2028-10 · NCT07028125 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma …Recruiting
Est. primary completion 2029-06-02 · NCT06900595 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma …Active not recruiting
Est. primary completion 2029-07-15 · NCT05092958 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
2030 (5)
May 2030 (2)
Early phase / not applicableRenal Cell CarcinomaRecruiting
Est. primary completion 2030-05-19 · NCT07805122 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Refractory Differentiated Thyroid Gland CarcinomaRecruiting
Est. primary completion 2030-09-30 · NCT06475989 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1Metastatic Ewing SarcomaRecruiting
Est. primary completion 2030-10 · NCT07194044 · CT.gov ↗
What to watch
Phase 1Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-10-18 · NCT07848295 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch
2033 (1)
August 2033 (1)
Phase 1Neurofibromatosis 1, Plexiform NeurofibromaRecruiting
Est. primary completion 2033-08-01 · NCT06502171 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
Phase 3Von Hippel-Lindau Disease, Malignant NeoplasmsRecruiting
Est. primary completion 2034-04-22 · NCT07405164 · CT.gov ↗
What to watch
2035 (1)
January 2035 (1)
Phase 3Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, Osteosarcoma MetastaticRecruiting
Est. primary completion 2035-01 · NCT07871864 · CT.gov ↗
What to watch

See the full readout calendar ↗